Loss of Tsc1 or Tsc2 induces vascular endothelial growth factor production through mammalian target of rapamycin

Cancer Research

Volumn 63, Issue 17, 2003, Pages 5173-5177

  El Hashemite, Nisreen ^a   Walker, Victoria ^a   Zhang, Hongbing ^a   Kwiatkowski, David J ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; GENE PRODUCT; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE; PROTEIN TSC1; RAPAMYCIN; TUBERIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTOSOMAL DOMINANT DISORDER; CELL KILLING; CONTROLLED STUDY; DISEASE COURSE; EMBRYO; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; TUBEROUS SCLEROSIS; VASCULARIZATION;

ANIMALS; CELL LINE; ENDOTHELIAL GROWTH FACTORS; FEMALE; FIBROBLASTS; IMMUNOHISTOCHEMISTRY; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHOKINES; MALE; MICE; PROTEIN KINASES; PROTEINS; REPRESSOR PROTEINS; TUMOR SUPPRESSOR PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0141705466     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Gomez, M., Sampson, J., and Whitemore, V. The Tuberous Sclerosis Complex, 3rd ed. New York: Oxford University Press, 1999.
2. Plank, T. L., Yeung, R. S., and Henske, E. P. Hamartin, the product of the tuberous sclerosis 1 (TSC1) gene, interacts with tuberin and appears to be localized to cytoplasmic vesicles. Cancer Res., 58: 4766-4770, 1998.
3. van Slegtenhorst, M., Nellist, M., Nagelkerken, B., Cheadle, J., Snell, R., van den Ouweland, A., Reuser, A., Sampson, J., Halley, D., and van der Sluijs, P. Interaction between hamartin and tuberin, the TSC1 and TSC2 gene products. Hum. Mol. Genet., 7: 1053-1057, 1998.
4. Cheadle, J. P., Reeve, M. P., Sampson, J. R., and Kwiatkowski, D. J. Molecular genetic advances in tuberous sclerosis. Hum. Genet., 107: 97-114, 2000.
5. Niida, Y., Stemmer-Rachamimov, A. O., Logrip, M., Tapon, D., Perez, R., Kwiatkowski, D. J., Sims, K., MacCollin, M., Louis, D. N., and Ramesh, V. Survey of somatic mutations in tuberous sclerosis complex (TSC) hamartomas suggests different genetic mechanisms for pathogenesis of TSC lesions. Am. J. Hum. Genet., 69: 493-503, 2001.
6. Onda, H., Lueck, A., Marks, P. W., Warren, H. B., and Kwiatkowski, D. J. Tsc2(+/-) mice develop tumors in multiple sites that express gelsolin and are influenced by genetic background. J. Clin. Investig., 104: 687-695, 1999.
7. Kwiatkowski, D. J., Zhang, H., Bandura, J. L., Heiberger, K. M., Glogauer, M., el-Hashemite, N., and Onda, H. A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells. Hum. Mol. Genet., 11: 525-534, 2002.
8. Kaelin, W. G. How oxygen makes its presence felt. Genes Dev., 16: 1441-1445, 2002.
9. Dvorak, H. F. Vascular permeability factor/vascular endothelial growth factor: a critical cytokin in tumor angiogenesis and a potential target for diagnosis and therapy. J. Clin. Oncol., 20: 4368-4380, 2002.
10. Kwiatkowski, D. J. Tuberous sclerosis complex: from tubers to mTOR. Ann. Hum. Genet., 67: 1-10, 2003.
11. Inoki, K., Li, Y., Zhu, T., Wu, J., and Guan, K. L. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat. Cell Biol., 4: 648-657, 2002.
12. Tee, A. R., Fingar, D. C., Manning, B. D., Kwiatkowski, D. J., Cantley, L. C., and Blenis, J. Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc. Natl. Acad. Sci. USA, 99: 13571-13576, 2002.
13. Arbiser, J. L., Brat, D., Hunter, S., D'Armiento, J., Henske, E. P., Arbiscr, Z. K., Bai, X., Goldberg, G., Cohen, C., and Wciss, S. W. Tuberous sclerosis-associated lesions of the kidney, brain, and skin are angiogenic neoplasms. J. Am. Acad. Dermatol., 46: 376-380, 2002.
14. Semenza, G. L. Involvement of hypoxia-inducible factor 1 in human cancer. Intern. Med., 41: 79-83, 2002.
15. Harris, A. L. Hypoxia: a key regulatory factor in tumour growth. Nat. Rev. Cancer, 2: 38-47, 2002.
16. LeCouter, J., Lin, R., and Ferrara, N. Endocrine gland-derived VEGF and the emerging hypothesis of organ-specific regulation of angiogenesis. Nat. Med., 8: 913-917, 2002.
17. Jiang, B. H., Agani, F., Passaniti, A., and Semenza, G. L. V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression. Cancer Res., 57: 5328-5335, 1997.
18. Mayerhofer, M., Valent, P., Sperr, W. R., Griffin, J. D., and Sillaber, C. BCR/ ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1α, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin. Blood, 100: 3767-3775, 2002.
19. Hudson, C. C., Liu, M., Chiang, G. G., Otterness, D. M., Loomis, D. C., Kaper, F., Giaccia, A. J., and Abraham, R. T. Regulation of hypoxia-inducible factor 1α expression and function by the mammalian target of rapamycin. Mol. Cell. Biol., 22: 7004-7014, 2002.
20. Kenerson, H. L., Aicher, L. D., True, L. D., and Yeung, R. S. Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors. Cancer Res., 62: 5645-5650, 2002.